Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hideo Tomozane is active.

Publication


Featured researches published by Hideo Tomozane.


Bioorganic & Medicinal Chemistry Letters | 2010

3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors

Ryoichi Ando; Hiroshi Ikegami; Makoto Sakiyama; Shinsuke Ooike; Masayuki Hayashi; Yasuhiro Fujino; Daisuke Abe; Hideo Nakamura; Tadashi Mishina; Harutoshi Kato; Yumiko Iwase; Hideo Tomozane; Masahiko Morioka

A new class of Aurora A kinase inhibitor was created by transforming 4-(5-methyl-3-pyrazoloamino)pyrimidine moiety of VX-680 to 3-cyano-6-(5-methyl-3pyrazoloamino)pyridine. Compound 6 exhibited a potent Aurora A kinase inhibitory activity, excellent selectivity to Aurora B kinase and other 60 kinases, good cell permeability and good PK profile. Therefore compound 6 was effective in antitumor mice model at a dose of 30 mg/kg po qd without decrease of body weight.


Bioorganic & Medicinal Chemistry Letters | 2000

N-{[1-(2-phenylethyl)pyrrolidin-2-yl]methyl}cyclohexane-carboxamides as selective 5-HT1A receptor agonists

Masakazu Fujio; Yoshifumi Togo; Hideo Tomozane; Takanobu Kuroita; Yasunori Morio; Jiro Katayama; Yasuhiro Matsumoto

A series of benzamides was synthesized as selective agonists for the 5-HT1A receptor. It was found that (S)-N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarb oxamide(7-(S)) has potent and selective agonistic activity for the 5-HT1A receptor (5-HT1A; Ki 0.49 nmol/L, D2; IC50 = >1000 nmol/L, 5-HT2; Ki = 240 nmol/L).


Archive | 2006

Cyanopyridine derivative and use thereof as medicine

Masahiko Morioka; Hiroshi Ikegami; Makoto Sakiyama; Masayuki Hayashi; Shinsuke Ooike; Yasuhiro Fujino; Daisuke Abe; Hideo Tomozane


European Journal of Medicinal Chemistry | 1999

Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists

Katsuhiko Itoh; Koji Kanzaki; Tsuguo Ikebe; Takanobu Kuroita; Hideo Tomozane; Shuji Sonda; Noriko Sato; Keiichiro Haga; Takeshi Kawakita


Archive | 2002

3,4-Dihalobenzylpiperidine derivatives and their medical use

Masatoshi Kiuchi; Takanobu Kuroita; Hideo Tomozane; Shuuzou Takeda; Yoshihito Tanaka; Hidemitsu Higashi; Shigeki Kuwahara


Archive | 1994

3-aminoazepine compound and pharmaceutical use thereof

Hideo Tomozane; Shu Murakami; Hiroshi Kitajima; Hiroshi Yasumatsu


Archive | 2005

Aminopyrimidine derivative and medicinal use thereof

Hideo Tomozane; Ryoichi Ando; Shinsuke Oike


Archive | 1992

Novel amide compounds and medicinal use thereof

Shu Murakami; Hideo Tomozane; Yoshifumi Togo; Yasuto Morimoto


Archive | 2006

Dérivé de cyanopyridine et emploi dudit dérivé au titre de médicament

Masahiko Morioka; Hiroshi Ikegami; Makoto Sakiyama; Masayuki Hayashi; Shinsuke Ooike; Yasuhiro Fujino; Daisuke Abe; Hideo Tomozane


Archive | 2006

Cyanopyridine derivative and its use as a medicine

Masahiko Morioka; Hiroshi Ikegami; Makoto Sakiyama; Masayuki Hayashi; Shinsuke Ooike; Yasuhiro Fujino; Daisuke Abe; Hideo Tomozane

Collaboration


Dive into the Hideo Tomozane's collaboration.

Top Co-Authors

Avatar

Daisuke Abe

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shinsuke Ooike

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Takanobu Kuroita

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hidemitsu Higashi

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge